European Commission stresses innovation in the field of biotechnology

22 April 2007

The European Commission has said it wants to put a special focus on innovation, research, market development and the debate with society on ethical issues in the field of biotechnology.

EuropaBio, the European Union Association for Bioindustries, has welcomed the announcement and congratulated the Commission on putting together such an extensive policy review. It said that the industry considers that the refocused actions proposed by the Commission are an important step towards building the bio-economy. However, the industry regrets the lack of implementation of the EU biotechnology strategy by a number of member states and would like to see both the review and the new action plan to be implemented throughout Europe without a biased pick and choose approach so as to obtain a coherent policy in favour of biotechnology in Europe.

EU members must take responsibility, says EuropaBio

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight